Saudi SFDA Medical Device Registration Documentation Checklist and Common Review Considerations

Saudi SFDA Medical Device Registration Documentation Checklist and Common Review Considerations

Published: 2026-07-05 09:00 | Updated: 2026-07-05 09:00

Source note: Compiled from AIMEILI regulatory practice materials and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation basis.

Answer: For medical device registration with the Saudi Food and Drug Authority (SFDA), the documentation package typically needs to cover product basic information, risk classification, technical file, ISO 13485 quality management system evidence, performance verification, clinical evaluation or clinical evidence, labels and instructions for use (IFU), authorization documents, existing registration certificates, and manufacturer declarations. Companies should not simply compile documents according to a checklist. They should first determine the product classification, the applicable registration pathway, the local authorized representative arrangement, and documentation gaps, then decide whether additional testing, translation, notarization, or localization is required. For medium- and high-risk products, consistency of the evidence chain, label claims, and post-market maintenance arrangements directly affect review efficiency.

Scope and Core Questions

Companies searching for the 'Saudi SFDA medical device registration documentation checklist' usually do not want only a downloadable table. They want to assess whether their existing NMPA, CE, ISO 13485, test reports, and IFU can support a Saudi submission, and which localized documents are still missing. This question involves three key judgments: how the product is classified in Saudi Arabia, whether a local authorized representative is required, and whether the existing technical file can be accepted by the SFDA.

If a company is already preparing to enter the Middle East market, the documentation checklist should serve the registration pathway rather than mechanically combining all files. An incorrect pathway assessment will misdirect subsequent translation, notarization, authorization, labeling, and deficiency responses.

Registration Decision Logic

Before Saudi registration, confirm the product's intended use, mechanism of action, risk level, existing foreign registration basis, and whether it involves sterile products, software, IVD, implants, home monitoring, or electrical safety requirements. Different products require different depths of documentation. Requirements for clinical evidence, performance verification, and post-market regulatory documentation for low-risk and high-risk products cannot be treated as the same.

For Chinese manufacturers, a more reliable approach is to first use existing Chinese and English documents to conduct a gap assessment, then decide which documents need translation, restructuring, additional testing, or supplementary declarations. This can reduce repeated deficiency responses and avoid redoing documents that could have been reused.

Core Documentation and Evidence

Saudi SFDA medical device registration typically needs to cover the following documents:

• Manufacturer entity information
• Product name and model/specification matrix
• Intended use
• Product description
• Basis for risk classification
• Technical file
• ISO 13485 quality management system certificate
• Performance verification or test reports
• Risk management file
• Clinical evaluation or clinical evidence
• Labels and instructions for use
• Declaration of conformity
• Authorized representative documents
• Existing market approval or other country registration certificates

The most common problem is consistency of the evidence chain. The indications in the IFU, the functional claims in promotional materials, the models covered by test reports, the equivalent product used in clinical evaluation, and the hazard analysis in the risk management file should correspond with one another. What the regulatory authority truly examines is not simply whether documents exist, but whether these documents together demonstrate that the product is safe, effective, and traceable for the intended use.

Common Errors

• Submitting directly translated Chinese registration documents without rearranging them according to the Saudi pathway.
• Preparing only certificates and IFUs while ignoring the technical file, risk management, and clinical evidence.
• Unclear arrangements for the local authorized representative, leading to later disputes over certificate maintenance and market control rights.
• Inconsistency between labels, IFUs, and registration documents, causing deficiency responses or post-market compliance risks.

Company Preparation Checklist

Before starting, companies are advised to prepare a company checklist:

• Target product list
• Model/specification matrix
• Existing registration certificates
• ISO 13485 certificate
• Test reports
• English IFU
• Label artwork
• Risk management documents
• Clinical evaluation materials
• Manufacturing sites and quality system coverage

This checklist is not the final submission checklist, but it can help quickly assess project workload.

AIMEILI View

AIMEILI recommends planning Saudi Arabia within a unified GHWP member-state and Middle East market access strategy. Companies should not only ask 'what documents are required,' but also confirm 'which documents can be reused, which must be localized, and which may affect the review conclusion.' For companies preparing to enter Saudi Arabia, the UAE, Thailand, Malaysia, and other markets at the same time, establishing a reusable core technical file first and then localizing it according to country requirements is generally more stable than supplementing documents on an ad hoc basis country by country.

Frequently Asked Questions

Can NMPA documents be used directly for Saudi registration?

They can be used as foundational documents, but they cannot directly replace Saudi submission documents. Companies still need to perform classification assessment, document structure adjustment, preparation of English or locally required documents, and label/IFU adaptation in accordance with SFDA requirements.

Is a local authorized representative required for Saudi registration?

Foreign manufacturers usually need a locally compliant entity to assist with registration communication and post-market maintenance. The scope of authorization, certificate control rights, and subsequent change mechanisms should be clarified before cooperation.

Can an incomplete package be submitted first?

Submission is not recommended when key documents are missing. Missing classification basis, performance verification, clinical evidence, or labeling documents can lengthen the deficiency response cycle and may also affect the determination of the registration pathway.

Related Reading

• What procedures are required to export Chinese medical devices to Indonesia?
• How to prepare the Indonesia medical device registration documentation checklist?
• How is the Singapore HSA medical device registration process conducted?
• What documents are required for medical device import registration in Vietnam?
• How to choose a local agent for medical device registration in the Middle East?
• Malaysia MDA medical device registration documentation checklist?
• How is the Thailand medical device registration process conducted?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.